Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on April 21, 2025. The report discloses a corporate action taken by the Board of Directors on April 19, 2025, regarding the company's 6% Convertible Exchangeable Preferred Stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is the dividend declaration:
- Dividend Amount: $0.15 per share.
- Security Type: 6% Convertible Exchangeable Preferred Stock.
- Payment Date: May 1, 2025.
- Record Date: April 29, 2025.
Material Changes
The material change reported is the declaration of a quarterly cash dividend. The Board determined that a surplus existed to support this payment. No other material changes to operations, assets, or liabilities are detailed in this specific filing.
Guidance, Outlook, and Risks
Management commentary indicates that while the Board will analyze the advisability of declaring dividends in future quarters, there is no assurance that future quarterly dividends will be declared. The decision is contingent on requisite financial analysis and the determination of a surplus.
Investor Verification Checklist
- Verify the record date of April 29, 2025, to confirm eligibility for the $0.15 dividend.
- Confirm the payment date of May 1, 2025, for cash receipt.
- Review the company's latest 10-K or 10-Q to assess the "surplus" determination and overall liquidity position supporting this dividend.
- Note that future dividends are not guaranteed and depend on future Board analysis.